Comparatively, unlike PD-1 inhibitors, which focus on the receptor found directly on T-cells, PD-L1 inhibitors target the tumor and antigen-presenting cell, leading to a broader, systemic immune response. This evidence concerns the gene PDCD1 and neoplasm.